Top Companies in the Infectious Disease Diagnostics

The infectious disease diagnostics market is projected to reach USD 42.20 billion by 2030 from an estimated value of USD 26.58 billion in 2025, growing at a CAGR of 9.7% during the forecast period. The key factors driving the market growth include the increasing prevalence of infectious diseases and the rising investments in R&D activities to adopt diagnostic solutions. The global rise in infectious disease cases has fueled the demand for reliable & efficient diagnostic tools. In response to these challenges, there is a rising focus on developing advanced technologies that support early disease detection & diagnosis, thereby improving patient outcomes.

• In July 2024, F. Hoffmann-La Roche Ltd. (Switzerland) acquired LumiraDx’s (US) Infectious disease technology that will enable the company to expand its offerings in decentralized patient care and drive global access to timely & actionable diagnostic results.
• In November 2023, Abbott (US) received the US FDA approval for its Alinity m High Risk (HR) HPV assay, expanding its molecular testing diagnostics portfolio.

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Revvity, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Seegene Inc. (South Korea), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), OraSure Technologies, Inc. (US), Co-Diagnostics, Inc. (US), SD Biosensor, INC. (South Korea), BIOSYNEX SA (France), Trinity Biotech (Ireland), Bruker (US), Genetic Signatures Ltd. (Australia), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Unijogen Oy (Finland), Vela Diagnostics (Singapore), and Molbio Diagnostics Limited (India).

To know about the assumptions considered for the study download the pdf brochure

F. Hoffmann-La Roche Ltd. (Switzerland) held a prominent position in the infectious disease diagnostics market. The company has sustained its market leadership through a robust distribution network spanning North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Roche maintains a combination of direct & indirect distribution channels, allowing it to mitigate demand fluctuations across regions. To further consolidate its position, the company leverages inorganic growth strategies, including strategic partnerships and acquisitions, to expand its market share and global reach.

Danaher Corporation (US) held a strong position in the infectious disease diagnostics market, supported by its diverse diagnostic portfolio and global operational footprint. The company benefits from a well-integrated network of subsidiaries such as Cepheid and Beckman Coulter, enabling it to address a wide range of infectious disease testing needs across several regions. Danaher’s global distribution & service capabilities help ensure consistent product access, even in rapidly changing demand environments. To reinforce its leadership, the company actively pursues inorganic growth strategies, including collaboration & agreements, aimed at expanding its technological capabilities and strengthening its position in high-growth segments of the diagnostics market.

Market Ranking:

F. Hoffmann-La Roche Ltd. (Switzerland) maintains a leading position in the infectious disease diagnostics market through its comprehensive molecular and immunoassay solutions, supported by global reach & regulatory expertise. Abbott (US) leverages its dual capabilities in centralized laboratory systems and rapid point-of-care testing to expand diagnostic accessibility across diverse global markets. Danaher Corporation (US) strengthens its market presence by offering scalable, automated diagnostic platforms that support high-throughput infectious disease testing. bioMérieux (France) focuses on clinical microbiology and syndromic testing, providing robust capabilities for pathogen identification and antimicrobial resistance monitoring. Thermo Fisher Scientific Inc. (US) contributes as a key technology provider, offering a broad portfolio of molecular diagnostics, laboratory instruments, and workflow automation solutions used across healthcare settings. As demand rises for accurate, timely, and decentralized infectious disease diagnostics, these companies continue to shape the market through sustained innovation, strategic investment, and global expansion.

Related Reports:

Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, PCR, NGS), Disease (Hepatitis, HIV, HAI, TB, Flu, Syphilis), End User (Labs) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103,
Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com